Arévalo MFG

Idioma: Español
Referencias bibliográficas: 17
Paginas: 30-32
Archivo PDF: 166.39 Kb.

FRAGMENTO

La psoriasis afecta al 1-3% de la población general. Su inicio varía con la edad pero es más frecuente en la 3ª década de la vida. Afecta a ambos géneros por igual. De los pacientes con psoriasis un 7 a 42% desarrollan artritis. La etiopatogenia de la enfermedad no es clara y han sido implicados factores genéticos, inmunológicos y ambientales. La artritis psoriásica (APs) es una enfermedad inflamatoria sistémica con manifestaciones articulares y extraarticulares. Hay cinco patrones clínicos descritos de artritis psoriásica: artritis de articulaciones interfalángicas distales, artritis destructiva o mutilante, poliartritis simétrica, oligoartritis asimétrica y espondiloartropatía.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf 2009; 8(6): 769-779.

2. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis: A systematic review. J Rheumatol 2006; 33: 1422- 1430.

3. Nash P. Therapies for axial disease in psoriatic arthritis: A systematic review. J Rheumatol 2006; 33: 1431-1434.

4. Spadaro A, Riccieri V, S ili-Scavalli A et al. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study. Clin Exp Rheumatol 1995; 13: 589-593.

5. Kaltwasser JP, Nash P, Gladman D et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial.Arthritis Rheum 2004; 50: 1939-1950.

6. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis: A systematic review. J Rheumatol 2006; 33: 1447-1451.

7. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272.

8. Mease PJ, Gladman DD, Ritchlin CT et al. A dalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-3289.

9. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640.

10. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.

11. Cañete JD, Celis R, Hernández MV, Pablos JL, Sanmartí R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis 2009.

12. Mease PJ, Gladman DD, Keystone EC. A lefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006; 54: 1638-1645.

13. Golov KG, Ivanov OL, Balkarov IM, Novoselov VS. Clinical significance of hyperuricemia in psoriasis. Klin Meed 1994; 72(3): 34-36.

14. Bruce IN, Schentag CT, Gladman DD. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol 2000; 6(1): 6-9.

15. Prasad PV, Bikku B, Kaviarasan PK, Senthilnathan A. A clinical study of psoriatic arthropathy. Indian J Dermatol Venereol Leprol 2007; 73(3): 166-170.

16. De Bari C, Lapadula G, Cantatore FP. Coexisting psoriatic arthritis, gout, and chondrocalcinosis. Scand J Rheumatol 1998; 27(4): 306-309.

17. Liu M, Li JH, Li B, He CD, Xiao T. Coexisting gout, erythrodermic psoriasis and psoriatic arthritis. Eur J Dermatol 2009; 19(2): 184-185.